特奈特普酶
医学
溶栓
心肌梗塞
内科学
纤溶剂
冲程(发动机)
链激酶
再灌注治疗
死亡率
观察研究
血脂异常
胸痛
组织纤溶酶原激活剂
心脏病学
疾病
工程类
机械工程
作者
S. S. Iyengar,Tiny Nair,Jagdish Hiremath,Anjan Lal Dutta,Uday Jadhav,V K Katyal,Dayanand Kumbla,I Sathyamurthy,Rajendra K. Jain,Manivannan Srinivasan,Prasant Kr Sahoo
出处
期刊:PubMed
日期:2017-09-01
卷期号:65 (9): 43-47
摘要
This real-world, observational, prescription event monitoring study was conducted to evaluate safety and efficacy of indigenous tenecteplase (TNK-tPA) in Indian patients presenting with ST elevation myocardial infarction (STEMI).This is a multi-centric, observational, prescription event monitoring study. Data was collected for 7,668 patients from 1,307 investigator sites across India from January 2011 to February 2016.Overall, 76.71% patients were hypertensive, 47.97% patients were diabetic, 42.01% had dyslipidemia, 24.35% had ischemic heart disease and 40.82% patients were smokers. The overall rate for achieving clinically successful thrombolysis by TNK was 93.34%. Delayed administration of tenecteplase yielded lower success rate (84.66%) as against those patients who received tenecteplase within 3 hours of symptoms (94.34%). 93.2% patients had chest pain resolution after pharmacological fibrinolysis. Overall 91.1% patients had 50% resolution of ST elevation at 90 minutes and mean time for 50% ST resolution was 72.06 minutes. Overall 53 patients died (mortality of 0.69%) before discharge. The incidence of bleeding (excluding stroke) was 1.77%, any stroke without ICH was 0.18% and any ICH was 0.38%.The findings of this study further reinforce the safety and efficacy of indigenous TNK-tPA in Indian patients presenting with STEMI, including high-risk sub-groups. The study also highlights the importance of early reperfusion therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI